Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes - Sands, A T; Zambrowicz, B P; Rosenstock, J; Lapuerta, P; Bode, B W; Garg, S K; Buse, J B; Banks, P; Heptulla, R; Rendell, M; Cefalu, W T; Strumph, P (Diabetes Care, 2015)